Figure 3

DNAM-1 expression is associated with clinical parameters. (A) Proportion of DNAM-1⁺ cells in AML samples grouped according to the FAB subtype; median and individual values are shown. (B–C) Distribution of DNAM-1 expression in immature (M0-2) versus mature (M4–M6) FAB subtypes is shown; statistical significance was assessed using Mann–Whitney test. (D) Distribution of DNAM-1⁺ cells among CD34⁺ and CD34^- populations of AML blasts is depicted. Values derived from the same sample are connected with lines; n = 12, statistical significance was assessed using Wilcoxon paired rank test. (E–G) Distribution of DNAM-1 expression (% of positive cells) across NCCN risk groups (E), primary (pAML) and secondary (sAML) cases (F), and two age groups (G) is demonstrated. (H) Correlation of DNAM-1 expression with WBC counts is illustrated. (I–K) Distribution of DNAM-1 expression across AML types based on WHO classification (I), AML cases positive or negative for NPM1 and CEBPA mutations (J,K) is shown. Statistical significance was assessed using Mann–Whitney (D,G,J,K), Kruskal–Wallis (E,F) or Brown–Forsythe and Welch ANOVA (I) tests. Rs, Spearman correlation coefficient.